STAT Plus: Blueprint Medicines partners with Roche to develop and sell genetically targeted cancer drug
ANNE WESTON/FRANCIS CRICK INSTITUTE VIA WELLCOME
Blueprint Medicines is partnering with Roche to develop and market a cancer drug near approval for use in patients with tumors with a genetic mutation.
No hay comentarios:
Publicar un comentario